BioMarin Pharmaceutical Inc
BMRN
View Detailed Chart
61.150USD
+9.200+17.71%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
11.75BMarket Cap
22.49P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+17.71%
5 Days
+14.71%
1 Month
+16.52%
6 Months
+11.18%
Year to Date
-6.97%
1 Year
-6.87%
View Detailed Chart
TradingKey Stock Score of BioMarin Pharmaceutical Inc
Currency: USD Updated: 2025-12-19Key Insights
BioMarin Pharmaceutical Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 22/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 91.15.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioMarin Pharmaceutical Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
28
analysts
Buy
Current Rating
91.147
Target Price
+71.01%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
BioMarin Pharmaceutical Inc Highlights
StrengthsRisks
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 36.16% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.85B.
Undervalued
The company’s latest PE is 22.49, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 187.90M shares, increasing 0.04% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 17.35K shares of this stock.
BioMarin Pharmaceutical Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
BioMarin Pharmaceutical Inc Info
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
Ticker SymbolBMRN
CompanyBioMarin Pharmaceutical Inc
CEOHardy (Alexander)
Websitehttps://www.biomarin.com/
FAQs
What is the current price of BioMarin Pharmaceutical Inc (BMRN)?
The current price of BioMarin Pharmaceutical Inc (BMRN) is 61.150.
What is the symbol of BioMarin Pharmaceutical Inc?
The ticker symbol of BioMarin Pharmaceutical Inc is BMRN.
What is the 52-week high of BioMarin Pharmaceutical Inc?
The 52-week high of BioMarin Pharmaceutical Inc is 73.510.
What is the 52-week low of BioMarin Pharmaceutical Inc?
The 52-week low of BioMarin Pharmaceutical Inc is 50.760.
What is the market capitalization of BioMarin Pharmaceutical Inc?
The market capitalization of BioMarin Pharmaceutical Inc is 11.75B.
What is the net income of BioMarin Pharmaceutical Inc?
The net income of BioMarin Pharmaceutical Inc is 426.86M.
Is BioMarin Pharmaceutical Inc (BMRN) currently rated as Buy, Hold, or Sell?
According to analysts, BioMarin Pharmaceutical Inc (BMRN) has an overall rating of Buy, with a price target of 91.147.
What is the Earnings Per Share (EPS TTM) of BioMarin Pharmaceutical Inc (BMRN)?
The Earnings Per Share (EPS TTM) of BioMarin Pharmaceutical Inc (BMRN) is 2.719.
Related Instruments
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
